Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10436532 | 1.00 | HSD11B1 (0.43) | HSD11B1MEN1KMT2ATDP1POLB | |
| SCHEMBL11355878 | 0.97 | HSD11B1 (0.41) | HSD11B1MEN1KMT2ATDP1POLB | |
| Ammonia Solution, Strong SCHEMBL27892508 | 0.95 | HSD11B1 (0.41) | HSD11B1MEN1KMT2ATDP1POLB | |
| SCHEMBL15922741 | 0.92 | TP53 (0.39) | HSD11B1MEN1KMT2ATDP1POLB | |
| SCHEMBL1143530 | 0.90 | TP53 (0.41) | HSD11B1MEN1KMT2ATDP1POLB | |
| SCHEMBL15922897 | 0.86 | TP53 (0.41) | HSD11B1MEN1KMT2APOLBTSHR | |
| SCHEMBL455945 | 0.76 | TP53 (0.36) | MEN1KMT2APOLBTSHRTP53 | |
| SCHEMBL19073248 | 0.75 | TP53 (0.36) | POLBTSHRTP53SMN1; SMN2GAA | |
| SCHEMBL1150375 | 0.75 | KDM4E (0.48) | MEN1KMT2ATSHRTP53SMN1; SMN2 | |
| SCHEMBL18177915 | 0.75 | HTT (0.47) | HSD11B1TDP1POLBTSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840465-B2 | Antiviral compounds | UNIV BRIGHAM YOUNG (US) | 2017-12-12 | — | — | US | disclosed |
| US-20150368196-A1 | ANTIVIRAL COMPOUNDS | UNIV BRIGHAM YOUNG (US) | 2015-12-24 | — | — | US | disclosed |
| EP-2950789-A2 | ANTIVIRAL COMPOUNDS | Brigham Young University (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014121170-A2 | ANTIVIRAL COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368196-A1 | ANTIVIRAL COMPOUNDS | ACE, ADA, MAVS | HSD11B1 1386/4885MEN1 3154/4885KMT2A 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.